Biomarkers are measurable indicators of biological processes that can be used to diagnose, monitor, and predict disease progression and treatment response in neurodegenerative diseases. The biomarker investment landscape analyzes funding trends, key companies, regulatory pathways, and commercial opportunities in this rapidly growing sector.
The neurodegenerative disease biomarker market is experiencing significant growth driven by:
- Aging populations globally increasing demand for early diagnosis
- Precision medicine initiatives requiring biomarker-driven patient stratification
- Regulatory incentives such as the FDA's BT (Biomarker) designation
- Advances in technology enabling minimally invasive detection
¶ Amyloid and Tau Biomarkers
| Biomarker |
Technology |
Company |
Status |
| P-tau181 |
Blood test |
Quanterix, Roche |
Commercial |
| P-tau217 |
Blood test |
Lilly, Quanterix |
Commercial |
| P-tau231 |
Blood test |
Fujirebio |
Clinical |
| Aβ42/Aβ40 |
CSF/Plasma |
Roche, Lilly |
Commercial |
| Tau PET tracers |
Imaging |
Lilly, GE Healthcare |
Commercial |
- Seed amplification assays (SAA): Detect alpha-synuclein aggregates in CSF and skin
- Companies: Amprion, Synuclein, Quanterix
- Status: Clinical validation stage
- Platforms: Simoa (Quanterix), Elecsys (Roche)
- Applications: Disease progression monitoring, treatment response
- Status: Widely adopted in clinical trials
| Marker |
Application |
Companies |
| NfL |
Progression tracking |
Quanterix, Roche |
| p-tau |
Conversion prediction |
Lilly, Fujirebio |
| Neurogranin |
Synaptic dysfunction |
ADx, Euroimmun |
¶ Regulatory Landscape
The FDA's BT (Biomarker) designation provides:
- Accelerated approval pathways
- Qualification for drug development tools
- Reimbursement pathway support
- Co-development with therapeutics
- Regulatory approval requirements
- Market exclusivity benefits
- Roche: Broad biomarker portfolio, Elecsys platform
- Biogen: Aβ and tau diagnostics, Lumipulse platform
- Quanterix: Simoa technology, ultra-sensitive detection
- Fujirebio: CSF biomarkers, Tau Asia assay
- Lilly: P-tau217, donanemab companion diagnostic
- Amprion: Seed amplification technology
- Prothena: Tau antibody diagnostics
- AC Immune: Tau PET tracer partnership
- C2N Diagnostics: PrecivityAD blood test
- Blood-based biomarkers: $450M+ invested
- Digital biomarkers: $280M+ invested
- AI/ML-enabled diagnostics: $200M+ invested
- Point-of-care devices: $150M+ invested
- Roche partnership with Genentech for tau diagnostics
- Lilly acquisition of diagnostic assets
- Biogen diagnostics spin-out activities
- Multiplex platforms: Simultaneous detection of multiple biomarkers
- Point-of-care testing: Rapid, accessible diagnostics
- Digital biomarker integration: Wearable and app-based measures
- Ethnic diversity: Biomarker validation across populations
- Combination biomarker panels for differential diagnosis
- Real-time disease monitoring devices
- Companion diagnostics for emerging therapeutics
](https://www.fda.gov/drugs/drug-development-tools/biomarker-qualification-program)